<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042549</url>
  </required_header>
  <id_info>
    <org_study_id>GS-PA-001</org_study_id>
    <nct_id>NCT00042549</nct_id>
  </id_info>
  <brief_title>Lithotripsy for the Treatment of Gallstones</brief_title>
  <official_title>Biliary Lithotripsy in Combination With Actigall Versus Actigall Monotherapy for the Treatment of Symptomatic Cholesterol Gallstones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstone International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstone International</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of using the Medstone
      lithotripter to treat single non-calcified gallstones from 4 to 20 mm in diameter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, single-masked controlled trial in which the combination therapy
      of lithotripsy and the bile acid drug Actigall is compared to monotherapy with only Actigall.
      The primary objectives are, 1) To determine whether the use of the Medstone STS Lithotripter
      system in combination with the orally administered drug Actigall is more effective (as
      measured by percentages of stone free patients 6 months after randomization) in reducing
      single non-calcified radiolucent gallstones (from 4 to 20mm in diameter) than use of Actigall
      alone, and 2) To demonstrate that use of the Medstone lithotripsy system is safe (as measured
      by incidence of adverse events) for the intended purpose, when operated according to its
      labeling.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2002</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <enrollment>184</enrollment>
  <condition>Cholelithiasis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporeal Shock Wave Lithotripsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ursodiol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  History of biliary pain

          -  Evidence of a single noncalcified, radiolucent gallstone between 4 and 20 mm
             (inclusive) diameter

          -  HIDA scan demonstrating patency of cystic bile duct

          -  No cardiac pacemaker

          -  No allergy to radioopaque dye, iodine, bile acids

          -  No spontaneous or iatrogenic bleeding disorder

          -  No current or prior bile duct obstruction, cholangitis, pancreatitis, or cholecystitis

          -  Not pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atilla Ertan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgina Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://patients.uptodate.com/frames.asp?page=tocmain.asp</url>
    <description>UpToDate is a practical clinical information service (always current). It is written by a recognized faculty of experts who each address a specific clinical issue. They synthesize the latest evidence and best practices.</description>
  </link>
  <reference>
    <citation>Ertan A. Treatment of gallstones by extracorporeal shock wave lithotripsy. Am J Gastroenterol. 2002 Apr;97(4):831-2. Review.</citation>
    <PMID>12003415</PMID>
  </reference>
  <reference>
    <citation>Ertan A, Hernandez RE, Campeau RJ, Geshner JR, Litwin MS. Extracorporeal shock-wave lithotripsy and ursodiol versus ursodiol alone in the treatment of gallstones. Gastroenterology. 1992 Jul;103(1):311-6.</citation>
    <PMID>1612339</PMID>
  </reference>
  <reference>
    <citation>Vanderpool D, Jones RC, O'Leary JP, Hamilton JK. Biliary lithotripsy. Am J Surg. 1989 Sep;158(3):194-7. Review.</citation>
    <PMID>2672841</PMID>
  </reference>
  <reference>
    <citation>Sackmann M, Pauletzki J, Sauerbruch T, Holl J, Schelling G, Paumgartner G. The Munich Gallbladder Lithotripsy Study. Results of the first 5 years with 711 patients. Ann Intern Med. 1991 Feb 15;114(4):290-6.</citation>
    <PMID>1987875</PMID>
  </reference>
  <reference>
    <citation>Pelletier G, Raymond JM, Capdeville R, Mosnier H, Caroli-Bosc FX. Gallstone recurrence after successful lithotripsy. J Hepatol. 1995 Oct;23(4):420-3.</citation>
    <PMID>8655959</PMID>
  </reference>
  <verification_date>June 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2002</study_first_submitted>
  <study_first_submitted_qc>August 2, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Gallstones</keyword>
  <keyword>Gallstone</keyword>
  <keyword>Biliary stones</keyword>
  <keyword>Gallbladder stones</keyword>
  <keyword>Gallbladder</keyword>
  <keyword>Lithotripsy</keyword>
  <keyword>Cholelithiasis</keyword>
  <keyword>ESWL</keyword>
  <keyword>Shock wave</keyword>
  <keyword>Shock waves</keyword>
  <keyword>shockwaves</keyword>
  <keyword>shockwave</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallstones</mesh_term>
    <mesh_term>Cholelithiasis</mesh_term>
    <mesh_term>Cholecystolithiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

